Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
1. RGLS reported positive Phase 1b MAD study results for farabursen in ADPKD. 2. In the fourth cohort, urinary PC1 and PC2 levels significantly improved. 3. Farabursen group showed minimal htTKV growth while placebo group surged. 4. Overall safety and tolerability of farabursen remained favorable. 5. RGLS stock surged 51.94% following the announcement.